About The Study: This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded medications contain the same active ingredients as in branded medications but may contain different inactive ingredients. Most websites did not disclose that compounded GLP-1 RAs were not FDA approved, although some suggested these drugs were FDA approved. Many websites provided limited safety information and unauthorized efficacy claims. Some websites did not disclose that these medications were compounded or incorrectly referred to them as generic.
Corresponding Author: To contact the corresponding author, Ashwin K. Chetty, BS, email ashwin.chetty@yale.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2024.5018)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.5018?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=011725
Journal
JAMA Health Forum